表皮生长因子受体酪氨酸激酶抑制剂抗肿瘤治疗的临床进展

被引:4
作者
张晓彤
李龙芸
机构
[1] 中国医学科学院中国协和医科大学北京协和医院呼吸内科
关键词
酪氨酸激酶抑制剂; 抗肿瘤; 肿瘤治疗; 单克隆抗体; 痤疮样皮疹; 头颈部肿瘤; 头颈肿瘤; 肿瘤细胞; 肺癌患者; 小细胞肺癌; 用药剂量; 临床研究进展; 顺铂; 紫杉醇; 健择;
D O I
暂无
中图分类号
R730.5 [肿瘤治疗学];
学科分类号
100214 ;
摘要
引用
收藏
页码:310 / 312
页数:3
相关论文
共 26 条
[1]  
Antiangiogenic and antitumor activity of antiepidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Ciardiello F,Bianco R,Damiano V,et al. Clinical Cancer Research . 2000
[2]  
Pilot trial of ZD1839 (Irresa), an oral inhibitor of epidermal growth factor receptor (EGFR)tyrosine kinase, in combination with carboplatin(C) and paclitaxel(P) in previously untreated advanced non-small cell lung cancer(NSCLC). Laurie SA,Miller VA,Johnson D,et al. Lung Cancer . 2000
[3]  
On receptor inhibitors and chemotherapy. Ryan PD,Chabner BA. Clinical Cancer Research . 2000
[4]  
Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Chan KC,Knox WF,Gandhi A,et al. British Journal of Surgery . 2001
[5]  
Synergistic antitumor activity of IFNαin combination with ZD1839 ( IressaTM ), an EGFR tyrosine kinase inhibitor, in HNSCC and melanoma cell lines. Budillon A,Di Gennaro E,Bruzzese F,et al. Clinical Cancer Research . 2000
[6]  
Epidermal growth factor receptor blockede with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing othotopically in nude mice by antiangiogenic mechanisms. Bruns C,Harbison M,Davis D,et al. Clinical Cancer Research . 2000
[7]  
Targeted therapy with C225 and cisplatin in patients with head and neck cancers. Mendelson J,Shin DM,Donato N,et al. Clinical Cancer Research . 2001
[8]  
Antitumor effects of doxorubicin in combination with anti-epidernal growth factor receptor monoclonal antibodies. Baselga J,Norton L,Masui H,et al. Journal of the National Cancer Institute . 1993
[9]  
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 ( Iressa), an inhibitor of EGFR tyrosine kinase. Sirotnak F,Zakowski M,Miller V,et al. Clinical Cancer Research . 2000
[10]  
Evaluation of ZD1839 (Irresa) alone and in combination with irinotecan ( CPT-11 ) against pediatric solid tumor xenografts. Houghton PJM Cheshire PJ,Harwood FC. Clinical Cancer Research . 2000